Extendicare (TSE:EXE) PT Set at C$15.40 by National Bankshares

Extendicare (TSE:EXE - Get Free Report) received a C$15.40 target price from investment analysts at National Bankshares in a report issued on Thursday,BayStreet.CA reports. The firm currently has an "outperform" rating on the stock. National Bankshares' target price would suggest a potential upside of 16.67% from the stock's current price.

A number of other brokerages also recently commented on EXE. BMO Capital Markets lifted their price objective on shares of Extendicare from C$13.50 to C$14.50 in a research report on Monday, May 12th. TD Securities lifted their price objective on shares of Extendicare from C$13.00 to C$15.00 and gave the company a "hold" rating in a research report on Thursday, May 22nd. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Extendicare presently has a consensus rating of "Hold" and a consensus price target of C$13.98.

Extendicare Stock Up 3.1%

Extendicare stock traded up C$0.40 during mid-day trading on Thursday, reaching C$13.20. The company's stock had a trading volume of 261,308 shares, compared to its average volume of 184,076. The company has a market capitalization of C$1.10 billion, a price-to-earnings ratio of 16.83 and a beta of 1.26. Extendicare has a 12 month low of C$7.31 and a 12 month high of C$15.24. The business's 50 day simple moving average is C$14.08 and its 200 day simple moving average is C$12.73. The company has a debt-to-equity ratio of 283.02, a quick ratio of 0.98 and a current ratio of 0.62.

About Extendicare

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.